Intrexon | XON - Eigenkapital Und Reserven





Eigenkapital Und Reserven Veränderung Datum
Agenus USD -221.22M 49.89M 2026-03
Alaunos Therapeutics USD 1.29M 865K 2026-03
Amgen USD 9.19B 532M 2026-03
Anika Therapeutics USD 133.9M 9.56M 2026-03
Arrowhead Research USD 613.98M 45.56M 2026-03
AstraZeneca USD 47.33B 1.33B 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Gilead Sciences USD 23.52B 897M 2026-03
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
Heron Therapeutics USD 9.14M 4.15M 2026-03
Incyte USD 5.62B 455.37M 2026-03
Intrexon USD 43.17M 75.33M 2024-06
Karyopharm Therapeutics USD -292.93M 23.67M 2025-12
Ligand Pharmaceuticals USD 997.32M 19.89M 2026-03
MacroGenics USD 21.2M 34.39M 2026-03
MannKind USD -59.2M 8.17M 2026-03
Merck USD 45.88B 6.73B 2026-03
Novartis USD 38.93B 7.2B 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Roche Holding CHF 33.8B 758M 2025-12
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Thermo Fisher Scientific USD 51.93B 1.6B 2026-03
Veracyte USD 1.34B 34.83M 2026-03
Xencor USD 515.63M 119.95M 2026-03